Epstein–Barr virus: novel patented therapeutics

Bibliography

• Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92
   PubMed Web of Science ®Google Scholar
• Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 2007;26:1297-305
   PubMed Web of Science ®Google Scholar
• Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-68
   PubMed Web of Science ®Google Scholar
• Tao Q, Young LS, Woodman CB, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers–genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 2006;11:2672-713
   PubMed Web of Science ®Google Scholar
• Shah KM, Young LS. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Clin Microbiol Infect 2009;15:982-8
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Tellam JT, Khanna R. Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol 2004;125:267-81
   PubMed Web of Science ®Google Scholar
• Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;346:1890-900
   Google Scholar
• Khanna R, Moss D, Ghandi M. Technology insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat Clin Pract Oncol 2005;2:138-49
   PubMedGoogle Scholar
• Callan MF. The immune response to Epstein-Barr virus. Microbes Infect 2004;6:937-45
   PubMed Web of Science ®Google Scholar
• Straathof KC, Bollard CM, Rooney CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 2003;8:83-98
   PubMed Web of Science ®Google Scholar
• Billaud G, Thouvenot D, Morfin F. Drug targets in herpes simplex and Epstein Barr Virus infections. Infect Disord Drug Targets 2009;9:117-25
   PubMedGoogle Scholar
• Heslop HE. How I treat EBV lymphoproliferation. Blood 2009;114:4002-8
   PubMed Web of Science ®Google Scholar
• Wei WISJST. Nasopharyngeal carcinoma. Lancet 2005;365:2041-54
   PubMed Web of Science ®Google Scholar
• Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Hematol 2007;139:532-44
   PubMed Web of Science ®Google Scholar
• Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies in the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol 2005;2:406-15
   Google Scholar
• Ambinder RF. Epstein-Barr virus and Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007:204-209
   Google Scholar
• Thompson PT, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004;10:803-21
   PubMed Web of Science ®Google Scholar
• Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003;33:5108-21
   Google Scholar
• Kohlhof H, Hampel F, Hoffmann R, Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells. Blood 2009;113:5506-15
   Google Scholar
• Zheng H, Hi LL, Hu DS, Kao Y. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol 2007;4:185-96
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Semin Cancer Biol 2001;11:435-44
   PubMedGoogle Scholar
• Rowe M, Kelly GL, Bell AI, Rickinson AB. Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 2009;19:377-88
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-56
   PubMed Web of Science ®Google Scholar
• Metias SM, Lianidou E, Yousef GM. MicroRNAs in clinical oncology: at the crossroads between promises and problems. J Clin Pathol 2009;62:771-6
   Google Scholar
• Trang P, Weidhaas JB, Slack FJ. MicroRNAs as a potential cancer therapeutics. Oncogene 2008;27:S52-7
   PubMedGoogle Scholar
• Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B. The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines. Virology 2009;386:387-97
   PubMedGoogle Scholar
• Cosmopoulos K, Pegtel M, Hawkins J, Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 2009;83:2357-67
   PubMed Web of Science ®Google Scholar
• Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol 2007;81:7825-32
   PubMed Web of Science ®Google Scholar
• Sokal EM, Hoppenbrouwers K, Vandermeulen C, Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007;196:1749-53
   PubMed Web of Science ®Google Scholar
• Sashihara J, Burbelo PD, Savoldo B, Human antibody titers Epstein-Barr Virus (EBV) gp350 to correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology 2009;391:249-56
   PubMed Web of Science ®Google Scholar
• Xiao J, Palefsky JM, Herrera R, EBV-positive human sera contain antibodies against the EBV BMRF-2 protein. Virology 2009;393:151-9
   Google Scholar
• Baumforth KRN, Young LS, Flavell KJ, The Epstein-Barr virus and its association with human cancers. Mol Pathol 1999;52:307-22
   PubMedGoogle Scholar
• Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82
   PubMed Web of Science ®Google Scholar
• Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein-Barr virus. Int J Dev Biol 2005;49:285-92
   PubMed Web of Science ®Google Scholar
• Tan LC, Gudgeon N, Annels NE, A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-35
   PubMed Web of Science ®Google Scholar
• Jurgens LA, Khanna R, Weber J, Orentas RJ. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: a novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. J Clin Immunol 2006;26:22-32
   PubMed Web of Science ®Google Scholar
• Paludan C, Munz C. CD4+ T cells responses in the immune control against latent infection by Epstein-Barr virus. Curr Mol Med 2003;3:341-7
   Google Scholar
• Adhikary D, Behrends U, Boerschmann H, Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS ONE 2007;2:e583
   PubMed Web of Science ®Google Scholar
• Heller KN, Gurer C, Munz C. Virus-specific CD4+ T cells: ready for direct attack. J Exp Med 2006;203:805-8
   PubMedGoogle Scholar
• Allen UD. Epstein-Barr virus vaccination of transplant candidates: light at the end of the tunnel? Transplantation 2009;88:976-7
   Google Scholar
• Epstein MA, Morgan AJ, Finerty S, Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985;318:287-9
   PubMed Web of Science ®Google Scholar
• Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999;170:49-64
   PubMed Web of Science ®Google Scholar
• Spaete R, Jackman W. Non-splicing variants of gp350/220. US20090263412; 2009
   Google Scholar
• Information available from: http://www.patentstorm.us/
   Google Scholar
• Moutschen M, Léonard P, Sokal E, M. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007;25:4697-705
   PubMed Web of Science ®Google Scholar
• Steinman RM, Muenz C. Protective antigen of Epstein Barr virus. US20060188520; 2006 and US7442377; 2008
   Google Scholar
• Levitskaya J, Coram M, Levitsky V, Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-8
   PubMed Web of Science ®Google Scholar
• Münz C, Bickham KL, Subklewe M, Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000;191:1649-60
   PubMed Web of Science ®Google Scholar
• Münz C. Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J Exp Med 2004;199:1301-4
   PubMed Web of Science ®Google Scholar
• Demachi-Okamura A, Ito Y, Akatsuka Y, Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci 2008;99:1633-42
   PubMed Web of Science ®Google Scholar
• Lutsky VP, Corban M, Heslop L, Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol 2010;84:407-17
   Google Scholar
• Depil S, Moralès O, Castelli FA, Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. J Immunother 2007;30:215-26
   PubMed Web of Science ®Google Scholar
• Celis E. Epstein-Barr-virus specific immunization. US20060257356; 2006 and US7422751; 2008
   Google Scholar
• Kobayashi H, Nagato T, Takahara M, Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell response against natural killer lymphoma cells. Cancer Res 2008;68:901-8
   PubMedGoogle Scholar
• Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 cells. Curr Opin Immunol 2008;20:221-7
   PubMed Web of Science ®Google Scholar
• Khanna R, Duraiswamy J. EBV peptide epitopes, polyepitopes and delivery system thereof. US20070048329; 2007
   Google Scholar
• Smith C, Beagley L, Khanna R. Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression. J Virol 2009;83:6192-8
   PubMed Web of Science ®Google Scholar
• Kuzushima K, Ito Y, Okamura A, Cytotoxic T-cell epitope peptides that specifically attack EBV-infected cells and use thereof. US20090305324; 2009
   Google Scholar
• Ito Y, Demachi-Okamura A, Ohta R, Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and –Cw*0304-restricted epitope on EBNA1-expressing cells. J Gen Virol 2007;88:770-80
   Google Scholar
• Caligiuri M, Baiocchi R. Viral gene products and method for vaccination to prevent viral associated diseases. US20070196389; and WO2007097820; 2007
   Google Scholar
• Thomson S, Duraiswamy J, Moss D. Treatment of EBV-associated diseases. US20090202584; and WO2007065215; 2009
   Google Scholar
• Duraiswamy J, Sherritt M, Thomson S, Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003;101:3150-6
   PubMed Web of Science ®Google Scholar
• Thomson SA, Duraiswamy J, Moss D. Treatment of Epstein-Barr virus-associated diseases (WO2007065215). Available from: www.wipo.int
   Google Scholar
• Suhrbier A, Thomson S, Khanna R, Polyepitope vaccines. US20070172461; 2007
   Google Scholar
• Elliott SL Suhrbier A, Miles JJ, Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 2008;82:1448-57
   Google Scholar
• Information available from: http://clinicaltrials.gov/
   Google Scholar
• Adhikary D, Behrends U, Mautner J, Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens. WO2009068615; 2009
   Google Scholar
• Adhikary D, Behrends U, Feederle R, Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles. J Virol 2008;82:3903-11
   Google Scholar
• Gershburg E, Pagano JS. Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother 2005;56:277-81
   PubMed Web of Science ®Google Scholar
• De Paoli P. Nover virally targeted therapies of EBV-associated tumors. Curr Cancer Drug Targets 2008;8:581-96
   Google Scholar
• Chan AT, Teo PM, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004;31:794-801
   PubMedGoogle Scholar
• Schinazi R, Shi J, Fingeroth J, Gustafson E. Treatment of EBV and KSHV infection. US7211570; 2007
   Google Scholar
• Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother 1998;42:2923-31
   PubMed Web of Science ®Google Scholar
• Holy A, Krecmerova M, Piskala A, Azacytosine derivatives useful as antiviral agents. US20090005346; 2009
   Google Scholar
• Naesens L, Andrei G, Votruba I, Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2(phosphonomethoxy)propyl]-5-azacytosine. Biochem Pharmacol 2008;15:997-1005
   Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13
   PubMed Web of Science ®Google Scholar
• Wolfe MS. Gamma-Secretase in biology and medicine. Semin Cell Dev Biol 2009;20:219-24
   PubMed Web of Science ®Google Scholar
• De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010;6:99-107
   PubMed Web of Science ®Google Scholar
• Shih IeM, Wang TL. Notch signalling, gamma-secretases inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82
   PubMed Web of Science ®Google Scholar
• Curry CL, Reed LL, Golde TE, Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005;24:6333-44
   PubMed Web of Science ®Google Scholar
• Robertson E, Lan K. Gamma secretase inhibitor for treatment of herpesvirus infection. US20090060881; 2009
   Google Scholar
• Lan K, Murakami M, Bajaj B, Inhibition of KSHV infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther 2009;22:2163-43
   Google Scholar
• Kirschner AN, Omerovic J, Longnecker R, Jardetzky T. Peptides, peptidomimetics and small molecule inhibitors of the EBV mediated fusion and entry process. US20090074719; 2009
   Google Scholar
• Kirschner AN, Lowrey AS, Longnecker R, Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion. J Virol 2007;81:9216-29
   Google Scholar
• Reimer JJ, Backovic M, Deshpande CG, Analysis of Epstein-Barr virus glycoprotein B functional domains via linker insertion mutagenesis. J Virol 2009;83:734-47
   Google Scholar
• Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses: strike and counterstrike. Nat Biotechnol 2007;25:1435-43
   PubMed Web of Science ®Google Scholar
• Saravolac EG, Wong JP, Cairns MJ. Recent patents in Antiviral siRNAs. Recent Pat Anti Infect Drug Discov 2009. [Epub ahead of print]
   Google Scholar
• Dale R, Sun LQ. RNA oligonucleotides targeting EBV and host genes and their use for the treatment of nasopharyngeal carcinomas. WO2009011697; 2009
   Google Scholar
• Fahmi H, Cochet C, Hmama Z, Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J Virol 2000;74:5810-8
   Google Scholar
• Fukuda M, Kurosaki W, Yanagihara, A mechanism in Epstein-Barr virus oncogenesis: inhibition of transforming growth factor-beta 1-mediated induction of MAPK/p21 by LMP1. Virology 2002;302:310-20
   Google Scholar
• Tosato G, Teruya-Feldstein J, Setsuda J, Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Springer Semin Immunopathol 1998;20:405-23
   PubMed Web of Science ®Google Scholar
• Fan TM, Kranz DM, Roy EJ. Enhancing antitumor immunity: combining IL-12 with TGFbeta1 antagonism. J Immunother 2007;30:479-89
   PubMed Web of Science ®Google Scholar
• Baiocchi R, Caligiuri M, Van Buskirk AM. Methods to treat or prevent viral-associated lymphoproliferative disorders. US20090004182; 2009
   Google Scholar
• Martorelli D, Houali K, Caggiari L, Spontaneous T cell response to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy. Int J Cancer 2008;123:1100-7
   PubMed Web of Science ®Google Scholar
• Rees L, Tizard EJ, Morgan AJ, A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009;88:1025-9
   PubMed Web of Science ®Google Scholar
• Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004;100:1892-901
   PubMed Web of Science ®Google Scholar
• Comoli P, Pedrazzoli P, Maccario R, Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr Viris-targeted cytotoxic T lymphocytes. J Clin Oncol 2005;23:8942-9
   PubMed Web of Science ®Google Scholar
• June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204-12
   PubMed Web of Science ®Google Scholar
• Gutierrez MI, Judde JG, Magrath IT, Bhatia KG. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res 1996;56:969-72
   Google Scholar
• Feng WH, Israel B, Raab-Traub N, Chemotherapy induces lytic EBV replication and confers Ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002;62:1920-6
   PubMed Web of Science ®Google Scholar
• Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004;78:1893-902
   PubMed Web of Science ®Google Scholar
• Roychowdhury S, Peng R, Baiocchi RA, Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003;63:965-71
   PubMed Web of Science ®Google Scholar
• Mentzer SJ, Perrine SP, Faller DV. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 2001;3:177-85
   PubMedGoogle Scholar
• Dykxhoorn DM. RNA interference as an anticancer therapy: a patent perspective. Expert Opin Ther Pat 2009;19:475-91
   PubMed Web of Science ®Google Scholar